EGFR and neoplasm: Targeting the epidermal growth factor receptor (EGFR) inhibitor in breast cancer with gefitinib was found to reduce the secretion of several proteins that promote tumor angiogenesis and invasion, including vascular endothelial growth factor (VEGF) and interleukin-8 (IL-8) [137].